2025 Europe Autoimmune Disease Treatment Market Revenue Opportunities Report
Description
The 2025 Europe Autoimmune Disease Treatment Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autoimmune disease treatment market in Europe are argenx, MorphoSys, F. Hoffmann-La Roche Ltd, and Bayer AG. Argenx, headquartered in Belgium/Netherlands, is recognized for its antibody-based therapies targeting neuromuscular autoimmune disorders, with its flagship drug efgartigimod (Vyvgart) approved for myasthenia gravis and its pipeline expanding to other autoimmune indications. MorphoSys from Germany specializes in antibody treatments for autoimmune diseases and psoriasis, collaborating with major pharma companies like Novartis and GSK to develop innovative biologics.
F. Hoffmann-La Roche Ltd, based in Switzerland, is among Europe's largest biopharma companies delivering therapies and diagnostics for multiple autoimmune diseases alongside oncology and CNS disorders, maintaining a significant market presence across more than 100 countries. Bayer AG, also a top-tier European firm, has a substantial footprint in autoimmune disease treatment, leveraging its R&D capabilities in biologics and small molecules to enhance therapeutic options across various autoimmune conditions. These companies drive innovation through robust pipelines, strategic collaborations, and broad geographic reach in the European autoimmune treatment landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autoimmune disease treatment market in Europe are argenx, MorphoSys, F. Hoffmann-La Roche Ltd, and Bayer AG. Argenx, headquartered in Belgium/Netherlands, is recognized for its antibody-based therapies targeting neuromuscular autoimmune disorders, with its flagship drug efgartigimod (Vyvgart) approved for myasthenia gravis and its pipeline expanding to other autoimmune indications. MorphoSys from Germany specializes in antibody treatments for autoimmune diseases and psoriasis, collaborating with major pharma companies like Novartis and GSK to develop innovative biologics.
F. Hoffmann-La Roche Ltd, based in Switzerland, is among Europe's largest biopharma companies delivering therapies and diagnostics for multiple autoimmune diseases alongside oncology and CNS disorders, maintaining a significant market presence across more than 100 countries. Bayer AG, also a top-tier European firm, has a substantial footprint in autoimmune disease treatment, leveraging its R&D capabilities in biologics and small molecules to enhance therapeutic options across various autoimmune conditions. These companies drive innovation through robust pipelines, strategic collaborations, and broad geographic reach in the European autoimmune treatment landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
